Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 33.41%.
IST:GENIL's ROC (Joel Greenblatt) % is ranked better than 75.66% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.45
vs IST:GENIL: 32.00
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS ROC (Joel Greenblatt) % Chart
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Annual Data
IST:GENIL vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
Gen Ilac Veglik Urunlerinayi ve Ticaret AS ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 33.41% mean?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) has a ROC (Joel Greenblatt) % of 33.41% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. This is 24% below median its historical median of 43.84. Over the past decade, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's ROC (Joel Greenblatt) % has ranged from 17.55 to 92.23. According to the industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #238 out of 978 companies in the Drug Manufacturers industry, placing it in the top 24.3%.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS's ROC (Joel Greenblatt) % too high?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current ROC (Joel Greenblatt) % of 33.41% is 24% below median its 10-year median of 43.84. Over the past 10 years, this metric has ranged from a low of 17.55 to a high of 92.23. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.45. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 33.41% is 191.8% above this industry median. Based on the distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #238 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gen Ilac Veglik Urunlerinayi ve Ticaret AS's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #238 out of 978 companies for ROC (Joel Greenblatt) %. This places Gen Ilac Veglik Urunlerinayi ve Ticaret AS in the top 24% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.45. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 33.41% is 191.8% above this benchmark. Historically, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's own ROC (Joel Greenblatt) % has ranged from 17.55 to 92.23 over the past decade. While the company's 10-year median is 43.84 vs. the industry median of 11.45, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current ROC (Joel Greenblatt) % of 33.41% is 191.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current ROC (Joel Greenblatt) % is 33.41%, which is 24% below median its own 10-year median of 43.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) is currently considered Fairly Valued. The stock's GF Value™ is ₺8.15, compared to a current price of ₺8.97 — trading 10.1% above its estimated fair value. The current ROC (Joel Greenblatt) % is 33.41%, which is 24% below median its 10-year median of 43.84 and 191.8% above the Drug Manufacturers industry median of 11.45. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL), the current ROC (Joel Greenblatt) % is 33.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Overvalued in 2026?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺8.97 is trading 10.1% above its estimated GF Value™ of ₺8.15.
GuruFocus considers Gen Ilac Veglik Urunlerinayi ve Ticaret AS to be Fairly Valued.
Key valuation signals for IST:GENIL:
ROC (Joel Greenblatt) %: 33.41% (24% below median its 10-year median of 43.84)
GF Value™: ₺8.15 vs. price of ₺8.97 (10.1% above fair value)
Industry Position: 191.8% above the Drug Manufacturers median (#238 of 978)
No single metric tells the full story. See the IST:GENIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Business Description
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
87GF Score
Get the complete analysis for IST:GENIL
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:GENIL has been successfully added to your 
